Addex Therapeutics LtdADXNNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank64
3Y CAGR-5.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-5.3%/yr
Quarterly compound
Percentile
P64
Within normal range
vs 3Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 11.64% |
| Q2 2025 | -8.06% |
| Q1 2025 | 71.96% |
| Q4 2024 | -22.74% |
| Q3 2024 | -33.50% |
| Q2 2024 | -11.29% |
| Q1 2024 | -66.44% |
| Q4 2023 | 259.42% |
| Q3 2023 | -20.07% |
| Q2 2023 | 17.49% |
| Q1 2023 | 309.72% |
| Q4 2022 | -110.07% |
| Q3 2022 | 13.72% |
| Q2 2022 | -31.04% |
| Q1 2022 | 512.61% |
| Q4 2021 | -75.77% |
| Q3 2021 | 11.22% |
| Q2 2021 | 39.65% |
| Q1 2021 | 107.58% |
| Q4 2020 | -48.49% |
| Q3 2020 | -22.09% |
| Q2 2020 | -5.10% |
| Q1 2020 | 309.24% |
| Q4 2019 | -145.25% |
| Q3 2019 | 19.46% |
| Q2 2019 | -1.36% |
| Q1 2019 | 13.10% |
| Q4 2018 | 11.25% |
| Q3 2018 | 188.60% |
| Q2 2018 | -0.00% |
| Q1 2018 | 199.89% |
| Q4 2017 | 0.00% |
| Q3 2017 | -66.86% |
| Q2 2017 | 0.00% |
| Q1 2017 | 121.81% |
| Q4 2016 | 0.00% |
| Q3 2016 | -46.91% |
| Q2 2016 | 0.00% |
| Q1 2016 | -24.29% |
| Q4 2015 | 0.00% |